Pulmonary function and survival one year after dupilumab treatment of acute moderate to severe COVID-19: A follow up study from a Phase IIa trial.

Jennifer Hendrick,Jennie Z Ma,Heather M Haughey,Rachael Coleman,Uma Nayak,Alexandra Kadl,Jeffrey M Sturek,Patrick Jackson,Mary K Young,Judith E Allen,William A Petri

medRxiv : the preprint server for health sciences（2023）

Cited 0|Views9

No score

Abstract

We observed evidence of reduced long-term morbidity and mortality from COVID-19 with dupilumab treatment during acute hospitalization when added to standard of care regimens.

Translated text

Key words

dupilumab treatment,pulmonary function

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined